Health Care [ 9/12 ] | Health Care Equipment & Supplies [ 51/74 ]
NYSE | Common Stock
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
It operates through two segments: Prevention and Recovery, and Reconstructive segments.
The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.
The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools.
It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
The company distributes its products through independent distributors, direct salespeople, and patients.
The company was formerly known as Colfax Corporation.
Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 26 | 0.89 Increased by +190.82% | 0.81 Increased by +9.88% |
| Feb 26, 26 | 0.95 Decreased by -3.06% | 0.82 Increased by +15.33% |
| Nov 6, 25 | 0.75 Increased by +2.74% | 0.65 Increased by +15.38% |
| Aug 7, 25 | 0.79 Increased by +27.42% | 0.72 Increased by +9.72% |
| May 8, 25 | -0.98 Increased by +25.76% | 0.74 Decreased by -231.76% |
| Feb 20, 25 | 0.98 Increased by +24.05% | 0.92 Increased by +7.02% |
| Nov 6, 24 | 0.73 Increased by +30.36% | 0.61 Increased by +19.67% |
| Aug 7, 24 | 0.62 Increased by +1.64% | 0.59 Increased by +5.08% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 589.15 M Increased by +5.43% | -8.76 M Increased by +84.34% | Decreased by -1.49% Increased by +85.15% |
| Dec 31, 25 | 575.76 M Increased by +2.64% | -520.59 M Increased by +25.98% | Decreased by -90.42% Increased by +27.88% |
| Sep 30, 25 | 548.91 M Increased by +8.65% | -571.15 M Decreased by -1.71 K% | Decreased by -104.05% Decreased by -1.57 K% |
| Jun 30, 25 | 564.54 M Increased by +7.50% | -36.74 M Decreased by -97.12% | Decreased by -6.51% Decreased by -83.37% |
| Mar 31, 25 | 558.83 M Increased by +8.25% | -55.97 M Increased by +22.27% | Decreased by -10.01% Increased by +28.19% |
| Dec 31, 24 | 560.98 M Increased by +23.29% | -703.34 M Decreased by -23.83 K% | Decreased by -125.38% Decreased by -19.35 K% |
| Sep 30, 24 | 505.22 M Increased by +21.00% | -31.52 M Decreased by -994.48% | Decreased by -6.24% Decreased by -804.50% |
| Jun 30, 24 | 525.16 M Increased by +22.56% | -18.64 M Decreased by -86.47% | Decreased by -3.55% Decreased by -52.15% |